Health eHeart BioBank

NCT06976502 | Enrolling By Invitation

• 1 other identifier: 24-40979
• Study Type: observational
• Target: 500,000
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the Health eHeart BioBank is to collect and store specimen (e.g. blood, DNA, tissue) for future studies at the University of California, San Francisco (UCSF) that will help determine changes and identify molecular and genetic markers in the human body that might help increase our knowledge of heart disease and guide development of new diagnostic tools and treatments that may help rapidly detect heart disease and prevent and/or treat heart disease.

Conditions

Heart Diseases; Cardiac Diseases; Vascular Diseases; Cardiovascular Diseases

Keywords

Heart Disease; Cardiovascular Disease; Cardiology

Outcome Measures

Primary Outcomes (1)

• Establish and Maintain a Centralized Biorepository

  Establish and maintain a centralized biorepository to collect and store a variety of biospecimen samples and clinical data. This would allow for the samples and clinical data to be used to test hypotheses regarding the molecular and genetic basis of diagnosis and treatment of cardiovascular diseases.

  Up to 10 years

Study Arms (3)

Participants with a History of Cardiovascular Disease

Procedure: Blood Draw; Procedure: Tissue Collection; Procedure: DNA Collection; Other: Medical Chart Review

Participants with a Family History of Cardiovascular Disease

Procedure: Blood Draw; Procedure: Tissue Collection; Procedure: DNA Collection; Other: Medical Chart Review

Healthy Controls

Procedure: Blood Draw; Procedure: Tissue Collection; Procedure: DNA Collection; Other: Medical Chart Review

Interventions

Blood Draw PROCEDURE

Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.

Healthy Controls; Participants with a Family History of Cardiovascular Disease; Participants with a History of Cardiovascular Disease

Tissue Collection PROCEDURE

If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.

Healthy Controls; Participants with a Family History of Cardiovascular Disease; Participants with a History of Cardiovascular Disease

DNA Collection PROCEDURE

Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.

Healthy Controls; Participants with a Family History of Cardiovascular Disease; Participants with a History of Cardiovascular Disease

Medical Chart Review OTHER

Demographic, clinical, and pathologic information will be extracted from the participant's medical record.

Also known as: Medical Record Review

Healthy Controls; Participants with a Family History of Cardiovascular Disease; Participants with a History of Cardiovascular Disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study population are patients of the University of California, San Francisco and their relatives.

You may qualify if:

• Age ≥ 18 years or older.
• And at least one of the following:
• Established patient seen at UCSF and/or is a current participant in a clinical study that utilizes the HeH BioBank for biospecimen collection.
• Family member of a patient with cardiovascular disease.
• Patient with no cardiovascular disease.

You may not qualify if:

• Unwilling to consent to biospecimen collection through the HeH BioBank.

Sponsors & Collaborators

• University of California, San Francisco: lead

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94158, United States

Location

Related Publications (9)

• Rahmutula D, Marcus GM, Wilson EE, Ding CH, Xiao Y, Paquet AC, Barbeau R, Barczak AJ, Erle DJ, Olgin JE. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-beta1. Cardiovasc Res. 2013 Sep 1;99(4):769-79. doi: 10.1093/cvr/cvt074. Epub 2013 Apr 23.

  PMID: 23612580 BACKGROUND

• Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, Yeh C, Colburn B, Clark NM, Khan R, Hart AP, Moffatt E. Prospective Countywide Surveillance and Autopsy Characterization of Sudden Cardiac Death: POST SCD Study. Circulation. 2018 Jun 19;137(25):2689-2700. doi: 10.1161/CIRCULATIONAHA.117.033427.

  PMID: 29915095 BACKGROUND

• Aouizerat BE, Vittinghoff E, Musone SL, Pawlikowska L, Kwok PY, Olgin JE, Tseng ZH. GWAS for discovery and replication of genetic loci associated with sudden cardiac arrest in patients with coronary artery disease. BMC Cardiovasc Disord. 2011 Jun 10;11:29. doi: 10.1186/1471-2261-11-29.

  PMID: 21658281 BACKGROUND

• Roberts JD, Hsu JC, Aouizerat BE, Pullinger CR, Malloy MJ, Kane JP, Olgin JE, Marcus GM. Impact of a 4q25 genetic variant in atrial flutter and on the risk of atrial fibrillation after cavotricuspid isthmus ablation. J Cardiovasc Electrophysiol. 2014 Mar;25(3):271-277. doi: 10.1111/jce.12317. Epub 2013 Dec 13.

  PMID: 24237655 BACKGROUND

• Roberts JD, Dewland TA, Glidden DV, Hoffmann TJ, Arking DE, Chen LY, Psaty BM, Olgin JE, Alonso A, Heckbert SR, Marcus GM. Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. Am Heart J. 2016 May;175:9-17. doi: 10.1016/j.ahj.2016.02.002. Epub 2016 Feb 13.

  PMID: 27179719 BACKGROUND

• Roberts JD, Dewland TA, Longoria J, Fitzpatrick AL, Ziv E, Hu D, Lin J, Glidden DV, Psaty BM, Burchard EG, Blackburn EH, Olgin JE, Heckbert SR, Marcus GM. Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1026-32. doi: 10.1161/CIRCEP.114.001781. Epub 2014 Nov 8.

  PMID: 25381796 BACKGROUND

• Marcus GM, Smith LM, Glidden DV, Wilson E, McCabe JM, Whiteman D, Tseng ZH, Badhwar N, Lee BK, Lee RJ, Scheinman MM, Olgin JE. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm. 2008 Feb;5(2):215-21. doi: 10.1016/j.hrthm.2007.10.007. Epub 2007 Oct 7.

  PMID: 18242542 BACKGROUND

• Roberts JD, Longoria J, Poon A, Gollob MH, Dewland TA, Kwok PY, Olgin JE, Deo RC, Marcus GM. Targeted deep sequencing reveals no definitive evidence for somatic mosaicism in atrial fibrillation. Circ Cardiovasc Genet. 2015 Feb;8(1):50-7. doi: 10.1161/CIRCGENETICS.114.000650. Epub 2014 Nov 18.

  PMID: 25406240 BACKGROUND

• Marcus GM, Rosenthal DG, Nah G, Vittinghoff E, Fang C, Ogomori K, Joyce S, Yilmaz D, Yang V, Kessedjian T, Wilson E, Yang M, Chang K, Wall G, Olgin JE. Acute Effects of Coffee Consumption on Health among Ambulatory Adults. N Engl J Med. 2023 Mar 23;388(12):1092-1100. doi: 10.1056/NEJMoa2204737.

  PMID: 36947466 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples with be collected with the option of DNA, heart tissue, and other samples may be collected.

MeSH Terms

Conditions

Heart Diseases; Vascular Diseases; Cardiovascular Diseases

Interventions

Blood Specimen Collection; Tissue Banks

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques; Biological Specimen Banks; Health Facilities; Health Care Facilities Workforce and Services

Study Officials

• Jeffrey E Olgin, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

• Gregory Marcus, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

• Vasanth Vedantham, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

• Connor G O'Brien, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

• James P Pirruccello, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 20 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2025
• First Posted: May 16, 2025
• Study Start: April 1, 2025
• Primary Completion (Estimated): December 1, 2035
• Study Completion (Estimated): December 1, 2035
• Last Updated: June 6, 2025

Record last verified: 2025-06

Locations

US (1)